Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Approval for the Treatment of MSI‑H/dMMR Advanced Endometrial Carcinoma
Shots:
- The approval was based on the Cohorts D & K of the (KEYNOTE-158) trial to evaluate Keytruda (200mg, IV, q3w) as monothx. in 90 patients with unresectable or metastatic MSI-H or dMMR EC, following prior systemic therapy in any setting & are not candidates for curative surgery or radiation
- The results showed ORR (46%), CR rate (12%) & PR rate (33%) at a median follow-up time of 16.0mos, 68% of patients had responses lasting ≥12mos. and 44% lasting ≥24mos., m-DoR was not reached
- The company is currently advancing a broad portfolio in gynecologic & breast cancers with an extensive clinical development program for Keytruda & multiple other investigational and approved therapies
Ref: Merck | Image: Merck
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
